Lenalidomide (CC-5013)

製品コードS1029

Lenalidomide (CC-5013)化学構造

分子量(MW):259.26

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs.

サイズ 価格(税別)  
JPY 31722.00
JPY 24402.00
JPY 94620.00

カスタマーフィードバック(4)

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure.

    Clin Cancer Res, 2011, 17(10): 3259–71. Lenalidomide (CC-5013) purchased from Selleck.

     

    Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α.

    Obesity 2012 20, 2174-85. Lenalidomide (CC-5013) purchased from Selleck.

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure. B) MM.1S cells were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 4 hours. Whole lysates were immunoblotted with indicated antibodies

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

    MM.1S cells were cultured for 48 hours in the presence or absence of BMSCs with control media, AT9283, lenalidomide or  AT9283 plus lenalidomide. Cell proliferation was assessed by 3H-TdR uptake (left). MM.1S cells were cultured in the absence or presence of BMSCs and treated for 4 hours with drugs alone or in combination. Whole lysates were immunoblotted with indicated antibodies.

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs.
ターゲット
TNF-α [1]
(PBMCs)
13 nM
体外試験

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rJbWlEPTB;Mj6xOVA{QCEQvF2= Ml3vV2FPT0WU
L-363 NY\kPIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfHcmkzUUN3ME2yMlkzOjF{IN88US=> MkL6V2FPT0WU
JAR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwOUewNFEh|ryP NHPHUIdUSU6JRWK=
EoL-1-cell M1;Ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTRwMUC1NVUh|ryP MmHKV2FPT0WU
BT-549 NXHSfWtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvhZYRKSzVyPU[uNlE5PDlizszN NWDj[5V7W0GQR1XS
SK-NEP-1 M1:3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G0SmlEPTB;Nz64PVUyOiEQvF2= Ml3tV2FPT0WU
BV-173 M13Ecmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP0WXVKSzVyPUiuOlc2QDVizszN M3PEWXNCVkeHUh?=
HMV-II MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS4ZndKUUN3ME2xNE4xOTd{IN88US=> M2\3dHNCVkeHUh?=
HCC1806 M1zMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[4TWM2OD1zMT60OFY4KM7:TR?= Mm\1V2FPT0WU
KASUMI-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO2TWM2OD1zMT61O|Eh|ryP MnLTV2FPT0WU
SK-MEL-28 M1vsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmzd4dSUUN3ME2xNU46PzZ2IN88US=> M4PhUXNCVkeHUh?=
RPMI-8226 NHXyW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF{Lk[yOFEh|ryP MoPmV2FPT0WU
T47D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXmTWM2OD1zMz6yNFk6KM7:TR?= MW\TRW5ITVJ?
HOP-62 NUXnNlBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXSlB2UUN3ME2xN{41QCEQvF2= NITHcXpUSU6JRWK=
A2058 M{LVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[zTWM2OD1zMz64NVk6KM7:TR?= NGezTZFUSU6JRWK=
SW620 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXYTWM2OD1zND6yOFc{KM7:TR?= NUDxV3YyW0GQR1XS
LCLC-103H Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfQSWZKSzVyPUG0MlQ5QTJizszN NGLHUm5USU6JRWK=
HAL-01 NYPIO3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX0e2lKSzVyPUG0MlU4QTZizszN NUf6WGtxW0GQR1XS
PANC-08-13 M37Odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S1fGlEPTB;MUSuPVExQCEQvF2= Mm\pV2FPT0WU
COLO-684 NH3UNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hj[mlEPTB;MUWuN|k4QSEQvF2= MUjTRW5ITVJ?
DEL NEfjRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBTWM2OD1zNT60PVkh|ryP NHjBb4VUSU6JRWK=
K5 NGHPfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHxTWM2OD1zNj6xOFg3KM7:TR?= M2fCeHNCVkeHUh?=
SK-MEL-24 M2DaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;aTWM2OD1zNj60OlUzKM7:TR?= M2jWZXNCVkeHUh?=
ACN M4X1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF4LkWyPVch|ryP MXXTRW5ITVJ?
H9 NXS5e3JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH4TWM2OD1zNj62NlYh|ryP NUKxNI9CW0GQR1XS
EM-2 NF\Ib41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DidmlEPTB;MUeuNVQ{KM7:TR?= Mke4V2FPT0WU
HSC-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHNTWM2OD1zNz62OlAyKM7:TR?= NYjRO45FW0GQR1XS
IGROV-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HHOGlEPTB;MUeuO|g{KM7:TR?= NUfieWczW0GQR1XS
TE-1 NYm1bpdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H5SGlEPTB;MUeuPVk3QCEQvF2= NVzZW3d5W0GQR1XS
LN-405 NIT1eXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;PcnFKSzVyPUG5MlkxPzZizszN MoP2V2FPT0WU
MSTO-211H NYLGeYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX3NY1PUUN3ME2yNE4{PTd|IN88US=> NFPZVGFUSU6JRWK=
MOLT-4 M3r0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJyLkW3OVkh|ryP NF3WTJVUSU6JRWK=
RS4-11 NVfDcY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ{LkG1OlMh|ryP M2nldnNCVkeHUh?=
ES3 NE\ESHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ{Lk[5OlMh|ryP MoPjV2FPT0WU
SBC-1 NE\wVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zXdWlEPTB;MkOuPFY6PiEQvF2= M3vQV3NCVkeHUh?=
CTV-1 NHTDdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm0TWM2OD1{NT6wNVQ6KM7:TR?= NE\hOZZUSU6JRWK=
HuP-T3 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;IUGN[UUN3ME2yOU41ODB7IN88US=> M2OwcXNCVkeHUh?=
HCC2218 M3G4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT0W5hKSzVyPUK1MlU1ODdizszN MkTmV2FPT0WU
HDLM-2 M2P6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T4R2lEPTB;MkiuNlAzPiEQvF2= MVHTRW5ITVJ?
ABC-1 M1T6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ7Lk[5O|Qh|ryP NIjMXI9USU6JRWK=
MV-4-11 NFHRNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfDZnpOUUN3ME2yPU44OzF5IN88US=> M2HqW3NCVkeHUh?=
WM-115 M3HBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;aTWM2OD1|MD6zNFk6KM7:TR?= MVnTRW5ITVJ?
SW1990 NYG1c41DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNyLkOzJO69VQ>? NHnPPJRUSU6JRWK=
HCC70 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG3XYQ2UUN3ME2zNE44OzR4IN88US=> MnntV2FPT0WU
KYSE-520 Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPwV2xKSzVyPUOwMlg5OzlizszN NIXwcVJUSU6JRWK=
JEG-3 NH35V21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\WTWM2OD1|MT6xOlE1KM7:TR?= MWHTRW5ITVJ?
C8166 NVXFRldVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfHXJRKSzVyPUOxMlIzPzRizszN M2\TSXNCVkeHUh?=
SK-OV-3 NGHFN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH1TWM2OD1|MT62O|U2KM7:TR?= MkP6V2FPT0WU
NCI-H526 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfpN|FPUUN3ME2zNk43QDNizszN NX:3XWs5W0GQR1XS
NKM-1 NYDrTINXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPFTWM2OD1|Mj65OVY5KM7:TR?= NYDCZZd1W0GQR1XS
ECC10 NIDSU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHqfIZKSzVyPUO0Mlc1PDNizszN NV72S2cyW0GQR1XS
A2780 M17CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN3LkO2NFEh|ryP M37rRXNCVkeHUh?=
KY821 NGrzPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\pOFNEUUN3ME2zOU44PjhzIN88US=> MXvTRW5ITVJ?
MKN1 M3;XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjudJZ6UUN3ME2zOk4zOTN5IN88US=> MknBV2FPT0WU
EKVX NIniW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN5LkSyNVIh|ryP M3XHZXNCVkeHUh?=
EW-16 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\PTWM2OD1|OD6zPFg2KM7:TR?= M1niNnNCVkeHUh?=
CTB-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD1|OT63O|g6KM7:TR?= M3jCZnNCVkeHUh?=
COR-L105 M3O5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OzWmlEPTB;NECuOFc1PiEQvF2= M3PocnNCVkeHUh?=
NCI-SNU-5 M{jJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULNV5BTUUN3ME20NU4zODZ7IN88US=> NVm4VW1yW0GQR1XS
Mewo NGLuXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTuW4RWUUN3ME20NU46QDdzIN88US=> NWHqTVVlW0GQR1XS
BCPAP NG\NZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXGc2lKSzVyPUSzMlc6OTdizszN MVjTRW5ITVJ?
KARPAS-45 NF;MT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[4TWM2OD12ND6yO|c3KM7:TR?= MXrTRW5ITVJ?
NCI-H1693 MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnQN4RnUUN3ME20Ok43QTh4IN88US=> MoPJV2FPT0WU
H-EMC-SS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrpSIdKSzVyPUS4MlMzOjRizszN MlzHV2FPT0WU
697 NH24bm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPuN3FKSzVyPUWwMlM2PDVizszN M{\LcnNCVkeHUh?=
KP-N-YS MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTmTWM2OD13Mj6zNVQzKM7:TR?= MoXFV2FPT0WU
NCI-H1304 NVLVOlFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ITWM2OD13Mj63NFI1KM7:TR?= M3[wRXNCVkeHUh?=
NOS-1 NYrlXJl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXJZllyUUN3ME21Nk45PTV7IN88US=> MVnTRW5ITVJ?
NCI-H2342 NGTXOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r1UmlEPTB;NUOuNFUxQCEQvF2= NGTHUJNUSU6JRWK=
KYSE-270 NUfhO2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\I[HBxUUN3ME21N{43OzZ2IN88US=> NF7tTI5USU6JRWK=
LU-135 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:1TnBKSzVyPUW1MlE5PTNizszN NI\JS4RUSU6JRWK=
OE33 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rnXmlEPTB;NUWuPFE5KM7:TR?= MX7TRW5ITVJ?
ML-2 NWLyUJg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTV3Lkm0PFkh|ryP NYWyVmk4W0GQR1XS
KMOE-2 NES5WHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXc21KSzVyPUW2MlI5QTNizszN NF2zSmNUSU6JRWK=
Daoy Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInKfVJKSzVyPUW2MlMzODRizszN MmLqV2FPT0WU
KNS-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzLTWM2OD13Nz6wNVQzKM7:TR?= M{HyN3NCVkeHUh?=
NBsusSR NVnkUmVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[4VHFKSzVyPUW3MlU4ODVizszN NXLCOmh3W0GQR1XS
UACC-257 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n0T2lEPTB;NUiuOlI3PCEQvF2= NUizNGEyW0GQR1XS
LU-139 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTV6LkiyOkDPxE1? M3e4eHNCVkeHUh?=
CAL-85-1 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTV6Lki2OFMh|ryP MV\TRW5ITVJ?
NCI-H720 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjNfHJDUUN3ME21PE45QTR{IN88US=> MkPxV2FPT0WU
MLMA NUPJNmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj1ZYpKSzVyPUW5MlA6OSEQvF2= NGTLRYJUSU6JRWK=
A3-KAW MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTV7LkK4NFkh|ryP MVjTRW5ITVJ?
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHXTYJpUUN3ME21PU43Ojh5IN88US=> MlnoV2FPT0WU
A388 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLxbIhKSzVyPU[wMlQ1QSEQvF2= Mo\EV2FPT0WU
LAMA-84 M3rnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTZyLkm5NFUh|ryP MWHTRW5ITVJ?
GCT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLwTWM2OD14MT6wO|g3KM7:TR?= NHzDVlVUSU6JRWK=
K-562 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C3U2lEPTB;NkGuOVM{OyEQvF2= NEPHZ3ZUSU6JRWK=
NCI-H1666 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT2OZVKSzVyPU[xMlg4PSEQvF2= MYXTRW5ITVJ?
NCI-H1993 M2TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF23[3RKSzVyPU[zMlQxPDNizszN MXzTRW5ITVJ?
NCI-H358 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPqWolKSzVyPU[1MlAyOjFizszN NXu1U3NoW0GQR1XS
NB6 M2fON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjoW4RKSzVyPU[1Mlk5QCEQvF2= NHzHVYlUSU6JRWK=
HCE-T MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS0XFA5UUN3ME22O{4xPzl6IN88US=> MV3TRW5ITVJ?
DOK NYrWZYczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnYSFJLUUN3ME22O{41QTR6IN88US=> NYP6dFA6W0GQR1XS
HT-1376 NXzhTZViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHtTWM2OD14OT64N|E1KM7:TR?= NEHWRWNUSU6JRWK=
NEC8 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v5RWlEPTB;N{CuNVI1OyEQvF2= MlzsV2FPT0WU
G-402 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrs[o5KSzVyPUewMlk{QTVizszN Mo\FV2FPT0WU
GR-ST NVvWUFZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPq[WtUUUN3ME23NU4yPzJizszN MX3TRW5ITVJ?
QIMR-WIL MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTdzLkS0N|Qh|ryP M{G2d3NCVkeHUh?=
CHP-212 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnFdVVmUUN3ME23NU46PjVizszN NWXkTGE4W0GQR1XS
KU812 M2HDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTd{Lkm3NFIh|ryP MXHTRW5ITVJ?
Becker MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTd|LkG0PFkh|ryP MXTTRW5ITVJ?
ChaGo-K-1 NEnhdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTd2Lke0PFYh|ryP MkLIV2FPT0WU
A498 NYrZTZJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T4d2lEPTB;N{SuPVMxQCEQvF2= MX;TRW5ITVJ?
NCI-H69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fOOmlEPTB;N{WuO|Y3OyEQvF2= MWHTRW5ITVJ?
NCI-H209 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjmUWdQUUN3ME23PE43OTR5IN88US=> M2XaZ3NCVkeHUh?=
CAL-33 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfCdVJDUUN3ME23PE46QTN7IN88US=> MmnmV2FPT0WU
COLO-680N NEjKVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH1TWM2OD15OT6xNFA4KM7:TR?= MoqxV2FPT0WU
D-283MED NGXXbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjMTWM2OD15OT64NVIh|ryP MmrnV2FPT0WU
ATN-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\JTZRMUUN3ME24NU4yOTh5IN88US=> MkTiV2FPT0WU
NCI-N87 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\oRYdKSzVyPUixMlczQTZizszN MlrCV2FPT0WU
MHH-NB-11 M1Lzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO3NWd5UUN3ME24NU45QDR7IN88US=> M{jWS3NCVkeHUh?=
HEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki3TWM2OD16Mj60NVM1KM7:TR?= MlSyV2FPT0WU
NB69 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTh|LkCwN|Mh|ryP M{fzdHNCVkeHUh?=
MPP-89 NX3hNotmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\KTWM2OD16Mz6yOVc2KM7:TR?= M{OyPHNCVkeHUh?=
COLO-829 NUTDbZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkflTWM2OD16NT60PVEzKM7:TR?= MXnTRW5ITVJ?
ONS-76 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTh3Lke5NFgh|ryP MVrTRW5ITVJ?
EW-3 NHPqOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PdIlKSzVyPUi2MlIxOzJizszN MlflV2FPT0WU
EW-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TXHNpUUN3ME24Ok41OzN4IN88US=> NIjJPVBUSU6JRWK=
SW900 M3ThOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTh5LkKwOVMh|ryP NFTLc|FUSU6JRWK=
MOLT-13 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTh5LkKyOFMh|ryP NHjQdlhUSU6JRWK=
HuP-T4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e3WmlEPTB;OUGuNFQxPSEQvF2= Mnn1V2FPT0WU
HCC1419 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPMTWM2OD17MT62N|c1KM7:TR?= M3vMcnNCVkeHUh?=
CAL-72 M1zxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTl{LkCyNVkh|ryP NW\k[nN5W0GQR1XS
Mo-T NF31OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrETWFKSzVyPUmyMlc3QTdizszN Ml\rV2FPT0WU
OC-314 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLUSlBEUUN3ME25Nk45QDJzIN88US=> NXXxPVJwW0GQR1XS
BHT-101 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLjTWM2OD17Mz6xJO69VQ>? M4jOdHNCVkeHUh?=
EW-18 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13a[2lEPTB;OUOuPFQ3OiEQvF2= NITRTHhUSU6JRWK=
TE-12 NX\VV41tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDUTWM2OD17ND6zNFU2KM7:TR?= MmW3V2FPT0WU
MDA-MB-361 NX;DOnJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonWTWM2OD17Nj6wOVE3KM7:TR?= NVr0dppQW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

お薦めの試験操作(参考用のみ)

動物試験:

[5]

+ 展開
  • 動物モデル: Adult male Sprague-Dawley rats bearing HUVECs cells
  • 製剤: 0.5% DMSO
  • 投薬量: 50 mg/kg and 250 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG 400+0.5% Tween 80+5% propylene glycol+H2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 259.26
化学式

C13H13N3O3

CAS No. 191732-72-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03720041 Not yet recruiting Multiple Myeloma University of Leeds|Cancer Research UK|Takeda|Celgene January 2019 Phase 3
NCT03733691 Not yet recruiting Newly Diagnosed Multiple Myeloma James R. Berenson MD Inc.|Takeda|Oncotherapeutics December 20 2018 Phase 2
NCT03729804 Not yet recruiting Multiple Myeloma University of Chicago December 24 2018 Phase 3
NCT03523975 Not yet recruiting Mantle Cell Lymphoma University of Michigan Cancer Center December 1 2018 Phase 1
NCT03373305 Not yet recruiting CD30-Positive Neoplastic Cells Present|Folliculotropic Mycosis Fungoides|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome City of Hope Medical Center December 2018 Phase 1
NCT03730740 Not yet recruiting Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma Samsung Medical Center November 16 2018 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the formulation for mouse injection(i.p.)?

  • 回答:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • 質問2:

    what is the procedure to resuspend this compound?

  • 回答:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

TNF-alphaシグナル伝達経路

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Lenalidomide (CC-5013)を買う | Lenalidomide (CC-5013) ic50 | Lenalidomide (CC-5013)供給者 | Lenalidomide (CC-5013)を購入する | Lenalidomide (CC-5013)費用 | Lenalidomide (CC-5013)生産者 | オーダーLenalidomide (CC-5013) | Lenalidomide (CC-5013)化学構造 | Lenalidomide (CC-5013)分子量 | Lenalidomide (CC-5013)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID